---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-25-000034"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T07:34:20.916141+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma reports record Q4 revenue $60M (+35% YoY); guides 2025 rev $255M-$275M

## Summary
- Record Q4 total revenue $60.1M (+35% YoY); full-year $203.1M (+24% YoY)
- Recorlev Q4 revenue $22.6M (+131% YoY); full-year $64.3M (+118% YoY)
- Q4 net loss $5.1M (($0.03)/share); Adjusted EBITDA $8.3M; cash $71.6M
- FY2025 revenue guidance $255M-$275M; expects positive Adjusted EBITDA going forward

## SEC filing metadata
- accession: 0001867096-25-000034
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000034/0001867096-25-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000034/xers-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-25-000034
- JSON: https://secwatch.observer/filing/0001867096-25-000034.json
- Plain text: https://secwatch.observer/filing/0001867096-25-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.